Veru Inc. (NASDAQ:VERU) CEO Mitchell Shuster Steiner Sells 84,021 Shares

Veru Inc. (NASDAQ:VERU) CEO Mitchell Shuster Steiner sold 84,021 shares of the stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $1.50, for a total transaction of $126,031.50. Following the transaction, the chief executive officer now owns 7,100,746 shares of the company’s stock, valued at $10,651,119. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Mitchell Shuster Steiner also recently made the following trade(s):

• On Friday, May 17th, Mitchell Shuster Steiner sold 28,066 shares of Veru stock. The stock was sold at an average price of $1.32, for a total value of $37,047.12.

Veru Price Performance

VERU stock traded down $0.05 during midday trading on Friday, reaching $1.32. 1,585,548 shares of the company were exchanged, compared to its average volume of 2,247,706. Veru Inc. has a one year low of $0.36 and a one year high of $1.92. The firm has a market capitalization of $193.22 million, a price-to-earnings ratio of -3.88 and a beta of -0.47. The business has a 50-day moving average price of $1.10 and a two-hundred day moving average price of $0.84.

Veru (NASDAQ:VERU) last announced its earnings results on Monday, April 1st. The company reported ($0.09) EPS for the quarter. The company had revenue of $2.14 million for the quarter. Veru had a negative return on equity of 130.13% and a negative net margin of 265.27%. As a group, analysts anticipate that Veru Inc. will post -0.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VERU has been the topic of a number of analyst reports. B. Riley assumed coverage on Veru in a research note on Tuesday. They set a “buy” rating and a $5.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $5.00 price target (down from $7.00) on shares of Veru in a research report on Monday, April 15th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Veru in a research report on Monday, May 13th. Finally, Raymond James assumed coverage on shares of Veru in a report on Thursday, March 28th. They issued an “outperform” rating and a $3.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

Hedge Funds Weigh In On Veru

A number of large investors have recently made changes to their positions in VERU. Perceptive Advisors LLC boosted its holdings in Veru by 412.4% in the 4th quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock valued at $4,021,000 after purchasing an additional 4,494,821 shares during the period. Rosalind Advisors Inc. grew its position in Veru by 12.5% during the first quarter. Rosalind Advisors Inc. now owns 4,500,000 shares of the company’s stock worth $3,150,000 after buying an additional 500,000 shares in the last quarter. Octagon Capital Advisors LP bought a new position in Veru during the 4th quarter worth $2,736,000. AIGH Capital Management LLC bought a new position in Veru during the 4th quarter worth $2,476,000. Finally, Ikarian Capital LLC acquired a new position in Veru in the 1st quarter valued at $663,000. Institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.